The phase III CheckMate 227 study showed that nivolumab plus ipilimumab (anti-CTLA-4) treatment was superior to CT alone in chemo-naïve NSCLC patients [18]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.